Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene RET
Variant D898_E901del
Impact List deletion
Protein Effect gain of function
Gene Variant Descriptions RET D898_E901del results in the deletion of four amino acids in the protein kinase domain of the Ret protein from amino acids 898 to 901 (UniProt.org). D898_E901del confers a gain of function to Ret as demonstrated by increased Erk phosphorylation (PMID: 32284345), increased Ret phosphorlyation, (PMID: 37535881), cytokine-independent growth in culture (PMID: 32284345, PMID: 37535881), and tumor formation in a mouse model (PMID: 37535881).
Associated Drug Resistance
Category Variants Paths

RET mutant RET act mut RET D898_E901del

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43120167_43120178del12
cDNA c.2694_2705del12
Protein p.D898_E901delDVYE
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_001406769.1 chr10:g.43126623_43126634del12 c.2692_2703del12 p.D898_L901delDDGL RefSeq GRCh38/hg38
NM_001406772.1 chr10:g.43126623_43126634del12 c.2692_2703del12 p.D898_L901delDDGL RefSeq GRCh38/hg38
NM_001406764.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_001406762.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406770.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_001406766.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406765.1 chr10:g.43123696_43123707del12 c.2692_2703del12 p.E898_T901delEIVT RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406761.1 chr10:g.43123690_43123701del12 c.2692_2703del12 p.L898_I901delLWEI RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901del RefSeq GRCh38/hg38
NM_001406771.1 chr10:g.43126665_43126676del12 c.2692_2703del12 p.N898_P901delNNAP RefSeq GRCh38/hg38
NM_001406767.1 chr10:g.43124923_43124934del12 c.2692_2703del12 p.K898_V901delKRPV RefSeq GRCh38/hg38
NM_001406763.1 chr10:g.43123696_43123707del12 c.2692_2703del12 p.E898_T901delEIVT RefSeq GRCh38/hg38
NM_001406768.1 chr10:g.43124901_43124912del12 c.2694_2705del12 p.C899_Q902delCWKQ RefSeq GRCh38/hg38
NM_020630.7 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901del RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43120167_43120178del12 c.2694_2705del12 p.D898_E901delDVYE RefSeq GRCh38/hg38
NM_001406773.1 chr10:g.43126665_43126676del12 c.2692_2703del12 p.N898_P901delNNAP RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET D898_E901del Advanced Solid Tumor sensitive Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, Retevmo (selpercatinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET D898_E901del in culture (PMID: 32284345). 32284345
RET D898_E901del Advanced Solid Tumor sensitive Selpercatinib Preclinical - Cell culture Actionable In a preclinical study, Retevmo (selpercatinib) inhibited Ret phosphorylation and proliferation in a transformed cell line expressing RET D898_E901del in culture (PMID: 37535881). 37535881
RET D898_E901del Advanced Solid Tumor sensitive Pralsetinib Preclinical - Cell culture Actionable In a preclinical study, Gavreto (pralsetinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET D898_E901del in culture (PMID: 32284345). 32284345
RET D898_E901del thyroid gland medullary carcinoma predicted - resistant Vandetanib Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del demonstrated primary resistance to Caprelsa (vandetanib) treatment (PMID: 37535881). 37535881
RET D898_E901del thyroid gland medullary carcinoma predicted - sensitive Selpercatinib Case Reports/Case Series Actionable In a clinical case study, Retevmo (selpercatinib) treatment resulted in a 61% reduction in the sum of the diameters of the target lesions in a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del, with treatment lasting 1 year (PMID: 37535881). 37535881
RET D898_E901del thyroid gland medullary carcinoma predicted - sensitive Selpercatinib Case Reports/Case Series Actionable In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in a clinical response after one month, with a partial response in liver lesions and abdominal lymph nodes that was maintained for 24 months, in a patient with metastatic medullary thyroid carcinoma harboring RET D898_E901del (PMID: 38438731; NCT03157128). 38438731
RET D898_E901del Advanced Solid Tumor resistant Cabozantinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing RET D898_E901del were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 37535881). 37535881
RET D898_E901del Advanced Solid Tumor predicted - sensitive Vandetanib Preclinical - Cell culture Actionable In a preclinical study, Caprelsa (vandetanib) inhibited Ret phosphorylation and proliferation in a transformed cell line expressing RET D898_E901del, but to a lesser degree than cells expressing RET C634R in culture (PMID: 37535881). 37535881